DePuy Synthes Spinoff Johnson & Johnson (JNJ) is slimming down again by getting back on the spinoff treadmill. The company announced last week that it plans to separate its orthopaedics division into a standalone company under the revived name DePuy Synthes, according to its press release. Unlike many spinoff announcements, the DePuy Synthes spinoff comes as a surprise,… Read More »
In American Psycho, Christian Bale’s character Patrick Bateman famously struggles to get a table at New York restaurant Dorsia. Hopefully brokers will be more accommodating to investors looking to get their hands on stock in Idorsia, which is to be spun out of Actelion (ALIOY) in the second quarter of 2017. Johnson & Johnson (JNJ) announced a deal… Read More »
Speculating about spinoffs – it’s not just for us, John Malone and deadline-driven journalists: 1) The Motley Fool handicaps the odds of a Johnson & Johnson (JNJ) spinoff in 2017. The basic premise is that JNJ has multiple segments with diverging sales trends (at least recently) so why not set one free. After playing through a few scenarios, the author ultimately suggests… Read More »